Human papillomavirus spectrum of HPV-infected women in Nigeria: an analysis by next-generation sequencing and type-specific PCR.
HPV types
Next-generation sequencing
Nigeria
Polymerase chain reaction
Spectrum
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
11 07 2023
11 07 2023
Historique:
received:
16
11
2022
accepted:
21
06
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
epublish
Résumé
Human papillomavirus (HPV) infection and cervical cancer are leading health problems and causes of death in many parts of the world. There are ~ 200 HPV types that can infect humans. This study aims to understand the spectrum of HPV infections in Nigerian women with normal or abnormal cytology. We screened cervical samples from 90 women with possible HPV infections collected in two regional hospitals in Nigeria. The first screening was done using next-generation DNA sequencing (NGS), identifying multiple HPV types in many samples. Thereafter, type-specific PCR analysis was used to verify the NGS-identified HPV types in each sample. NGS analysis of the 90 samples from the Nigerian cohort identified 44 HPV types. The type-specific PCR confirmed 25 HPV types out of the 44 HPV types detected by NGS, and ~ 10 of these types were the most prevalent. The top five prevalent types found in the Nigerian cohort were HPV71 (17%), HPV82 (15%), HPV16 (16%), HPV6 (10%), and HPV20 (7%). Among the PCR-confirmed HPV types, we found 40.98% high-risk HPV types, 27.22% low-risk HPV types, and 31.15% undetermined HPV types. Among these 25 HPV types in Nigeria, only six were included in the current nine-valent HPV vaccine. We also observed strikingly high multiple HPV infections in most patients, with as many as nine HPV types in a few single samples. Our NGS-PCR approach of HPV typing in the Nigerian cohort samples unveiled all possible HPV types currently circulating in Nigerian people. We confirmed 25 HPV types using NGS and PCR, with many samples infected with multiple HPV types. However, only six of these types are part of the nine-valent HPV vaccines indicating the need to develop region-specific selective vaccines.
Sections du résumé
BACKGROUND
Human papillomavirus (HPV) infection and cervical cancer are leading health problems and causes of death in many parts of the world. There are ~ 200 HPV types that can infect humans. This study aims to understand the spectrum of HPV infections in Nigerian women with normal or abnormal cytology.
METHODS
We screened cervical samples from 90 women with possible HPV infections collected in two regional hospitals in Nigeria. The first screening was done using next-generation DNA sequencing (NGS), identifying multiple HPV types in many samples. Thereafter, type-specific PCR analysis was used to verify the NGS-identified HPV types in each sample.
RESULTS
NGS analysis of the 90 samples from the Nigerian cohort identified 44 HPV types. The type-specific PCR confirmed 25 HPV types out of the 44 HPV types detected by NGS, and ~ 10 of these types were the most prevalent. The top five prevalent types found in the Nigerian cohort were HPV71 (17%), HPV82 (15%), HPV16 (16%), HPV6 (10%), and HPV20 (7%). Among the PCR-confirmed HPV types, we found 40.98% high-risk HPV types, 27.22% low-risk HPV types, and 31.15% undetermined HPV types. Among these 25 HPV types in Nigeria, only six were included in the current nine-valent HPV vaccine. We also observed strikingly high multiple HPV infections in most patients, with as many as nine HPV types in a few single samples.
CONCLUSIONS
Our NGS-PCR approach of HPV typing in the Nigerian cohort samples unveiled all possible HPV types currently circulating in Nigerian people. We confirmed 25 HPV types using NGS and PCR, with many samples infected with multiple HPV types. However, only six of these types are part of the nine-valent HPV vaccines indicating the need to develop region-specific selective vaccines.
Identifiants
pubmed: 37434253
doi: 10.1186/s12985-023-02106-y
pii: 10.1186/s12985-023-02106-y
pmc: PMC10337082
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
144Informations de copyright
© 2023. The Author(s).
Références
Diagn Cytopathol. 2013 Feb;41(2):107-14
pubmed: 21987449
Virology. 2014 Jan 5;448:356-62
pubmed: 24314666
Virol J. 2012 Nov 02;9:258
pubmed: 23121839
J Clin Microbiol. 2006 Sep;44(9):3292-8
pubmed: 16954263
Front Oncol. 2019 May 08;9:355
pubmed: 31134154
Br J Cancer. 2010 May 25;102(11):1657-60
pubmed: 20407442
Int J Mol Sci. 2023 May 09;24(10):
pubmed: 37239839
Ann Oncol. 2010 Mar;21(3):448-458
pubmed: 20176693
Virus Res. 2017 Mar 2;231:128-138
pubmed: 27856220
PLoS One. 2021 Sep 28;16(9):e0257324
pubmed: 34582476
Int J Cancer. 2011 May 1;128(9):2224-9
pubmed: 20607828
Vaccines (Basel). 2020 May 14;8(2):
pubmed: 32422939
J Clin Microbiol. 1997 Mar;35(3):791-5
pubmed: 9041439
Mem Inst Oswaldo Cruz. 2017 Oct;112(10):728-731
pubmed: 28954002
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
J Gynecol Oncol. 2018 Jan;29(1):e14
pubmed: 29185272
Clin Microbiol Infect. 2015 Sep;21(9):808-16
pubmed: 26003284
Mem Inst Oswaldo Cruz. 2010 Feb;105(1):73-8
pubmed: 20209333
J Clin Virol. 2005 Mar;32 Suppl 1:S43-51
pubmed: 15753011
Infect Agent Cancer. 2010 Jan 22;5:2
pubmed: 20180999
Int J Cancer. 2000 Feb 1;85(3):353-7
pubmed: 10652426
Int J Cancer. 2002 Aug 20;100(6):729-32
pubmed: 12209615
Asian Pac J Cancer Prev. 2010;11(1):117-22
pubmed: 20593940
Asian Pac J Cancer Prev. ;18(6):1543-1548
pubmed: 28669165
J Transl Med. 2014 Nov 26;12:300
pubmed: 25424736
Sci Rep. 2016 Apr 06;6:24067
pubmed: 27048884
Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):979-990
pubmed: 29288769
AIDS. 2010 Jul;24 Suppl 2:S5-23
pubmed: 20610949
Virology. 2016 Jun;493:202-8
pubmed: 27060563
J Clin Virol. 2009 Jul;45 Suppl 1:S93-7
pubmed: 19651375
Vaccine. 2013 Dec 30;31 Suppl 6:G32-44
pubmed: 24331818
J Clin Microbiol. 1998 Oct;36(10):3020-7
pubmed: 9738060
Sci Rep. 2019 Aug 29;9(1):12556
pubmed: 31467383
Expert Rev Mol Diagn. 2001 Nov;1(4):394-402
pubmed: 11901854
South Afr J HIV Med. 2020 Nov 05;21(1):1123
pubmed: 33240535
JCO Glob Oncol. 2020 Aug;6:1276-1281
pubmed: 32783640
Mol Biol Evol. 2021 Jun 25;38(7):3022-3027
pubmed: 33892491
Front Cell Infect Microbiol. 2020 Jun 09;10:234
pubmed: 32582561
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
Int J Cancer. 2012 Jul 15;131(2):E156-61
pubmed: 22038830
Int J Mol Sci. 2023 Mar 31;24(7):
pubmed: 37047526
Int J Infect Dis. 2021 Sep;110:426-432
pubmed: 34332083
J Clin Virol. 2011 Oct;52(2):93-7
pubmed: 21802982
Virol J. 2012 Aug 16;9:164
pubmed: 22897914
Int J Gynecol Cancer. 2023 Apr 3;33(4):592-597
pubmed: 36368710